Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Anaphase-promoting complex subunit 2 (ANAPC2) is a cullin-family protein forming the catalytic core of the anaphase-promoting complex/cyclosome (APC/C), which is a large multi-subunit E3 ubiquitin ligase that orchestrates the metaphase to anaphase transition and exit from mitosis by targeting specific cell cycle regulators—such as securin and mitotic cyclins—for ubiquitin-mediated proteolysis. This process ensures orderly chromosome segregation and cell cycle progression. ANAPC2 interacts with APC11 to form the minimal catalytic module required for ligase activity; dysregulation of APC/C and ANAPC2 is implicated in tumorigenesis and other proliferative diseases.
Inhibition of APC/C function to prevent cell cycle progression, leading to cell cycle arrest and apoptosis in cancer cells; Disruption of APC2:APC11 complex formation impairs ubiquitin ligase activity. Most inhibitors affect APC/C by preventing substrate recognition or coactivator interaction, indirectly modulating ANAPC2's catalytic role.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Anaphase-promoting complex subunit 2 (ANAPC2).